Baird raised its price target on Vertex (NASDAQ: VRTX) to $200.00 (from $186.00) while maintaining a Outperform rating.Analyst Brian ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Vertex (VRTX) PT Raised to $183 at UBSFebruary 1, 2018 9:08 AM Vertex (VRTX) PT Raised to $190 at Leerink PartnersFebruary 1, 2018 7:49 AM Vertex Pharma (VRTX): Solid Beat And No Guidance Until PDUFA Date, PT To $197 - BofAFebruary 1, 2018 6:51 AM Vertex (VRTX) PT Raised to $212 at Piper JaffrayFebruary 1, 2018 6:42 AM Vertex Pharma (VRTX) Announces Selection of 2 Next-Generation Correctors, VX-659 & VX-445, to Advance into Phase 3 Development as Part of Two Different Triple Combination RegimensFebruary 1, 2018 5:52 AM Vertex (VRTX) PT Raised to $203 at CitiFebruary 1, 2018 5:19 AM Vertex (VRTX) PT Raised to $193 at Deutsche BankFebruary 1, 2018 5:14 AM Vertex (VRTX) PT Raised to $200 at BarclaysFebruary 1, 2018 3:48 AM Vertex Pharma (VRTX) Tops Q4 EPS by 8c, Revenues BeatJanuary 31, 2018 4:17 PM